Biostatistic/Outcomes Cores

异基因造血干细胞移植(HSCT)是治疗许多慢性粒细胞白血病患者的唯一治疗方法。 恶性血液病和骨髓衰竭。成功完成HSCT的一个关键障碍是 移植物抗宿主病(GVHD)。这次更新研究项目的最终目标 应用是为了进一步加深我们对aGVHD和cGVHD的病理生理学的理解，并 针对不同的细胞群体，开发预防和治疗cGVHD的新策略 在这两个综合征的同时维持GVL。实现这一目标的关键，从而导致 该计划项目的成功是与三个项目中每一个的个人进行动态生物统计合作 项目和其他3个核心。 生物统计核心C的目的是提供以下服务，供 本计划项目中包含的研究项目。 1.为转译临床研究提供生物统计学协作。 2.为转译动物研究提供生物统计学合作。 3.为转化性实验室研究提供生物统计和/或生物信息学合作。 4.为翻译研究提供研究基础。 5.为数据处理、统计分析、标准化报告提供计算资源； 质量控制。 相关性(请参阅说明)： 预防或治疗慢性移植物抗宿主病，从而减少相关的发病率和死亡率是重要的，因为1) 造血干细胞移植技术的改进允许使用老年捐赠者和老年患者接受移植， 因此，更多的患者接受了HSCT，2)支持性护理的改进导致了更好的后期生存 发生cGVHD的时间段。

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for many patients with hematologic malignancies and marrow failure. A critical hurdle in accomplishment of successful HSCT has been graft-versus-host disease (GVHD).The ultimate objective of the research projects in this renewal application is to further improve our understanding of the pathophysiology of aGVHD and cGVHD and to develop novel strategies for both prevention and therapy of cGVHD by targeting distinct cellular populations in these two syndromes while maintaining GVL. Key to achieve this objective and thus to lead to the success of this program project is dynamic biostatistical collaboration with individuals in each of the 3 projects and the 3 other Cores. The purpose of the Biostatistics Core C is to provide the following services that will be utilized by the research projects included in this Program Project. 1. To provide biostatistical collaboration for translational clinical research studies. 2. To provide biostatistical collaboration for translational animal research studies. 3. To provide biostatistical and/or bioinformatics collaboration for translational laboratory research studies. 4. To provide research infrastructure for translational research. 5. To provide computing resources for data processing, and statistical analysis, standardized reporting, and quality control. RELEVANCE (See instructions): Preventing or treating cGVHD, thus reducing related morbidity and mortality, is important because 1) improvements in HSCT technology allow the use of older donors and older patients to receive transplant, thus more patients undergo HSCT, and 2) improvements in supportive care result in better survival in later time periods when cGVHD occurs.